Form 4: Intellia Therapeutics Executive Receives Stock Options and Restricted Stock Units

Derek Hicks, EVP and Chief Business Officer of Intellia Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On March 1, 2024, Derek Hicks, the EVP and Chief Business Officer of Intellia Therapeutics, acquired 29,393 shares of common stock and stock options for 42,421 shares.
• The common stock was acquired at a price of $0.
• Following the transaction, Hicks directly owns 66,380 shares of Intellia common stock.
• The stock options have an exercise price of $32.66 and expire on February 28, 2034.
• 33% of the options vest on January 1, 2025, with the remaining 67% vesting in 24 equal monthly installments thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. It's neither overwhelmingly positive nor negative from an investment perspective.

Positives

• The acquisition of stock options and restricted stock units may align the executive's interests with those of the shareholders.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded biotechnology companies such as CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The granting of stock options and restricted stock units could potentially align management's interests with those of shareholders, encouraging long-term value creation.

Key Dates